RE: Stimulus Funding to Compare Treatments_Scientific American
AHRP Quoted in Scientific American
$1.1 Billion in Stimulus Package for Comparing Medical Treatments
This has the potential for restoring integrity to medicine by providing doctors and the public with impartial risk / benefit information about existing treatments devoid of commercial bias.
Rolling Stone – Marketing a Phony “Miracle” Drug
“Bitter Pill” by Ben Wallace-Wells in the current issue of Rolling Stone is an excellent, informative, in-depth article providing an overview into the pharmaceutical industry’s immensely successful—albeit illegal—aggressive marketing tactics, for selling a particularly unsafe, dangerous class of drugs—the antipsychotics, Zyprexa in particular.
America’s Medicated Army + New Studies Linking SSRI to Suicide
Using drugs to cope with battlefield traumas is not discussed much outside the Army, but inside the service it has been the subject of debate for years.
Marcia Angell: Drug Co & Doctors: A Story of Corruption
"It is simply no longer possible to believe much of the clinical research that is published, or to rely on the judgment of trusted physicians or authoritative medical guidelines. I take no pleasure in this conclusion, which I reached slowly and reluctantly over my two decades as an editor of The New England Journal of Medicine." Marcia Angell, MD
Biederman J & J Risperdal Documents
A group of internal emails by Johnson & Johnson officials-mostly from officials in the company’s Risperdal marketing division-provide a bird’s eye view of collusion between the drug giant and Harvard’s leading child psychiatrist, Dr. Joseph Biederman, and one of Harvard’s premier teaching hospitals, Massachusetts General Hospital.
Antipsychotic Use in Children: FDA Panel Rejects FDA Soft-Peddle Approach
"The committee’s concerns are part of a growing chorus of complaints about the increasing use of antipsychotic medicines in children and teenagers.
Vera Sharav: A Profile in Nature Biotechnology
Dr. Marcia Angell, a senior lecturer at Harvard Medical School, and former editor of the New England Journal of Medicine and author of The Truth About Drug Companies, describes Sharav as an extraordinarily observant and valuable critic. "I see her as someone the research establishment badly needs."
Public Furor Forces NYU to Pull Ransom Note Ad Campaign
Good news but continued vigilance required! A backlash by outraged parents and advocates for responsible evidence-based rhetoric about physical and mental health issues, forced Dr. Harold Koplewicz, founder and director of the NYU Child Study Center, to pull the irresponsible, fear mongering "ransom note" ad campaign in which threats and…
Grassley Probes COI at American Psychiatric Association
Sen. Grassley is peeling away psychiatry’s layers of deception about the efficacy and safety of its treatments: "I have come to understand that money from the pharmaceutical industry can shape the practices of nonprofit organizations that purport to be independent in their viewpoints and actions."
Letter of Complaint Re: FDA Double Agent
A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels.
Letter of Complaint to FDA Commissioner, 2007
Complaint about a surge of FDA administrative approvals for expanded use of highly toxic antipsychotic drugs for children. Approvals were determined by Dr. Thomas Laughren after secret deliberations–without disclosure of scientific data, without an advisory panel or open public discussion.